Aspirin: expectations and limitations.
Rao
Gundu H R
GH
D001211:Asia, Western; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D003324:Coronary Artery Disease / Q000201:enzymology / Q000453:epidemiology* / Q000517:prevention & control*; D003430:Cross-Sectional Studies; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D003906:Developing Countries; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D005006:Ethnicity / Q000706:statistics & numerical data*; D006801:Humans; D007194:India; D008134:Long-Term Care; D015539:Platelet Activation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D020156:Salicylic Acid / Q000493:pharmacokinetics; D013608:Tablets, Enteric-Coated; D016896:Treatment Outcome
D016861:Cyclooxygenase Inhibitors; D010975:Platelet Aggregation Inhibitors; D013608:Tablets, Enteric-Coated; D020156:Salicylic Acid; D001241:Aspirin